How do pharma, biotech and MedTech manufacturers achieve lasting inspection readiness toward FDA, EMA and BfArM?

Inspection readiness is a state, and it cannot be produced shortly before the date. Readiness is built up in sequence. First, the GMP documentation under the EU GMP Guide and FDA 21 CFR Part 211 must be complete and current, because without reliable records there is nothing to present.

Data integrity under Annex 11 and 21 CFR Part 11 builds on top of this, because inspectors review not only the result but its traceability.

Only once both are in place does it pay off to train the teams for the inspection situation, because a staff member can only confidently present what actually exists. Starting with coaching before the documentation holds up trains people to show off gaps.

This is precisely why the gap analysis comes first: it reveals which element is the bottleneck before effort flows into the mock inspection and coaching. Open CAPAs from previous audits are the first touchstone here.

Within the EU, inspections are carried out by the competent authority of the member state, including those requested by EMA, and unannounced if necessary (Article 111(1) and (1c) of Directive 2001/83/EC). In Germany that is the state supervisory authority, which inspects holders of a manufacturing or import authorization as a rule every two years (Section 64(3a) of the German Medicines Act, AMG). The date of the last inspection is therefore a reference point for planning, not a commitment.

Readiness also covers what follows the closing meeting. In the EU, the inspected site first receives the draft report and may comment before it is adopted (Article 111(3) of Directive 2001/83/EC). If non-compliance with GMP stands after that, it is entered in EudraGMDP, the Union's public database; a positive outcome brings the GMP certificate within 90 days (Article 111(5) to (7)).

FDA hands over its observations at the end of the inspection on Form FDA 483. According to its 2009 notice (74 FR 40211), FDA intends to review responses received within 15 business days in detail before deciding whether to issue a Warning Letter. Three weeks for root cause analysis and an action plan are only enough if author, approval route and method are settled before the inspection.

The difference between an inspection passed with composure and a frantic one rarely lies on the day itself, but in whether the system was already inspection-ready every day beforehand.